2026 Q1 -tulosraportti
Vain PDF
30 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 50 | - | - | ||
| 548 | - | - | ||
| 14 000 | - | - | ||
| 4 270 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 20.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 päivää sittenI almost don't know whether to laugh or cry about this stock.
·19.5. · MuokattuJust stumbled upon some facts: Thomas Warthoe (CEO) and Peter Warthoe (CSO) are brothers. The two are known as biotech entrepreneurs and have together founded several companies in the healthcare sector, including the Danish diagnostics company Qlife Holding, which is behind the home testing platform Egoo Health. Atonomics A/S is the brothers' most significant bankruptcy. The company existed for over 15 years and raised massive amounts of capital along the way, which was lost in the crash. Estimated loss/Investments: Over the years, the company raised between 100 and 200 million DKK from external investors, funds, and partners. Among the major investors were the listed biotech company NeuroSearch (which during the period injected over 40-50 million DKK into the company in the form of share purchases and convertible loans) as well as foreign private equity funds like Syndicate. Historical results leading up to the bankruptcy: The company almost exclusively reported losses throughout its lifetime, as it was purely a development company. In the last years before the bankruptcy (2015–2017), annual losses typically ranged from 10–25 million DKK per year, as cash ran out and the Trace product did not achieve its final commercial breakthrough. Who suffered the loss? Primarily the professional venture investors and companies (like NeuroSearch) who had the value of their shares and loans wiped out. Their own companies have also closed with losses. The finances of the listed parent company Qlife Holding AB are characterized by large losses, very low revenue, and an ongoing need for capital injections to keep the business and the development of the Egoo Health platform alive. Revenue: The company's revenue is extremely modest. For the entire financial year 2025, total revenue only amounted to 324,000 Swedish kronor (kSEK). In the first quarter of 2026, revenue further decreased to just 21,000 SEK. Operating result (EBITDA): The annual result for 2025 landed at a massive operating loss of -18.1 million SEK. Operations cost the company around 5.5 million SEK per quarter. Since the company has carried out massive public share issues to survive, the majority of the company's share capital is today owned by thousands of private and smaller investors. The planned reverse takeover has enormous consequences for the current shareholders in Qlife Holding. In reality, the maneuver means that the company completely changes its identity and financial foundation. Here is a concrete review of what the agreement means for you as a shareholder: 1. Strong mathematical dilution (Ownership share shrinks) When Qlife acquires the much larger Chinese Hipro Biotech, payment is not made with cash, but by issuing an enormous amount of brand new Qlife shares, which are given to the Chinese owners. Before the merger: The current shareholders today own 100 % of Qlife Holding. After the merger: The current shareholders will together only own 16.7 % of the new, combined company. The Chinese owners take over the remaining 83.3 %. Your personal ownership share in the company will, in other words, be drastically cut. 2. You suddenly own a part of a profitable billion-dollar business. Although your percentage ownership share becomes smaller, the value behind your share changes fundamentally: Now: You own a part of a company with minimal revenue, double-digit million losses, and an acute risk of bankruptcy. After the merger: You own a smaller piece of a much larger, well-established, and already profitable Chinese diagnostics group with massive production and distribution networks. The total value of the company is expected to increase significantly if the merger is approved. 3. No compulsory redemption (You keep your shares) When an investor buys more than 30 % of a listed company, it normally triggers a statutory obligation to make a takeover bid to all other shareholders (mandatory takeover offer). Hipro's founder, Hao Shushun, who will end up owning 37.7 % of the company, is, however, seeking an exemption from this rule. This means that you will not be forced to sell your shares. Your current Qlife shares will remain in your custody account, but the company will most likely change its name on the Stockholm stock exchange. 4. Extended waiting time and risk Since the stock exchange (Nasdaq) has rejected the original Chinese company structure ("Red Chip"), the companies have had to extend the deadline to close the deal until December 31, 2026. As a shareholder, you must be prepared for the share price to be characterized by great uncertainty and price fluctuations for the next long period, while advisors try to find a new legal model that the Swedish stock exchange authorities can approve. The deal is also conditional on it finally being voted through at an upcoming general meeting in Qlife. In short: You go from owning a large percentage of a financially distressed Swedish/Danish biotech company to owning a small percentage of a large, Chinese-controlled medtech company on the Swedish stock exchange that determines everything and can redeem the shares at a price set by them without notice. Can you see what's happening to your investment?- ·13.5.Just saw the Q1 report and noticed that the company only has 3 employees??? They won't get much development done or sales from that. The Warthoe family seems to live mostly off the shareholders' continuous capital increases.
·22.5. · MuokattuYes, they will probably be in an early growth phase until they retire as millionaires (In this phase it's perfectly fine to milk the shareholders through share issues, as much as one wants) Ref report comment I think the stock exchanges should impose more requirements on the companies and protect the small shareholders much more. - ·12.5.Losses in all periods, despite capital injections?·13.5.It remains the same with this company. It is a company consisting solely of a few people who live on salaries costing millions paid by everyone else. Now they have worked on this project for over 20 years and they still haven't managed to make money from their idea. And the new board consists of old acquaintances who were also part of the original project, but who also seem to just want to enrich themselves. Whether it will ever amount to anything, I doubt. So I will also not throw more money after them in connection with more share issues. What I have now, must sink or swim.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenI almost don't know whether to laugh or cry about this stock.
- ·19.5. · MuokattuJust stumbled upon some facts: Thomas Warthoe (CEO) and Peter Warthoe (CSO) are brothers. The two are known as biotech entrepreneurs and have together founded several companies in the healthcare sector, including the Danish diagnostics company Qlife Holding, which is behind the home testing platform Egoo Health. Atonomics A/S is the brothers' most significant bankruptcy. The company existed for over 15 years and raised massive amounts of capital along the way, which was lost in the crash. Estimated loss/Investments: Over the years, the company raised between 100 and 200 million DKK from external investors, funds, and partners. Among the major investors were the listed biotech company NeuroSearch (which during the period injected over 40-50 million DKK into the company in the form of share purchases and convertible loans) as well as foreign private equity funds like Syndicate. Historical results leading up to the bankruptcy: The company almost exclusively reported losses throughout its lifetime, as it was purely a development company. In the last years before the bankruptcy (2015–2017), annual losses typically ranged from 10–25 million DKK per year, as cash ran out and the Trace product did not achieve its final commercial breakthrough. Who suffered the loss? Primarily the professional venture investors and companies (like NeuroSearch) who had the value of their shares and loans wiped out. Their own companies have also closed with losses. The finances of the listed parent company Qlife Holding AB are characterized by large losses, very low revenue, and an ongoing need for capital injections to keep the business and the development of the Egoo Health platform alive. Revenue: The company's revenue is extremely modest. For the entire financial year 2025, total revenue only amounted to 324,000 Swedish kronor (kSEK). In the first quarter of 2026, revenue further decreased to just 21,000 SEK. Operating result (EBITDA): The annual result for 2025 landed at a massive operating loss of -18.1 million SEK. Operations cost the company around 5.5 million SEK per quarter. Since the company has carried out massive public share issues to survive, the majority of the company's share capital is today owned by thousands of private and smaller investors. The planned reverse takeover has enormous consequences for the current shareholders in Qlife Holding. In reality, the maneuver means that the company completely changes its identity and financial foundation. Here is a concrete review of what the agreement means for you as a shareholder: 1. Strong mathematical dilution (Ownership share shrinks) When Qlife acquires the much larger Chinese Hipro Biotech, payment is not made with cash, but by issuing an enormous amount of brand new Qlife shares, which are given to the Chinese owners. Before the merger: The current shareholders today own 100 % of Qlife Holding. After the merger: The current shareholders will together only own 16.7 % of the new, combined company. The Chinese owners take over the remaining 83.3 %. Your personal ownership share in the company will, in other words, be drastically cut. 2. You suddenly own a part of a profitable billion-dollar business. Although your percentage ownership share becomes smaller, the value behind your share changes fundamentally: Now: You own a part of a company with minimal revenue, double-digit million losses, and an acute risk of bankruptcy. After the merger: You own a smaller piece of a much larger, well-established, and already profitable Chinese diagnostics group with massive production and distribution networks. The total value of the company is expected to increase significantly if the merger is approved. 3. No compulsory redemption (You keep your shares) When an investor buys more than 30 % of a listed company, it normally triggers a statutory obligation to make a takeover bid to all other shareholders (mandatory takeover offer). Hipro's founder, Hao Shushun, who will end up owning 37.7 % of the company, is, however, seeking an exemption from this rule. This means that you will not be forced to sell your shares. Your current Qlife shares will remain in your custody account, but the company will most likely change its name on the Stockholm stock exchange. 4. Extended waiting time and risk Since the stock exchange (Nasdaq) has rejected the original Chinese company structure ("Red Chip"), the companies have had to extend the deadline to close the deal until December 31, 2026. As a shareholder, you must be prepared for the share price to be characterized by great uncertainty and price fluctuations for the next long period, while advisors try to find a new legal model that the Swedish stock exchange authorities can approve. The deal is also conditional on it finally being voted through at an upcoming general meeting in Qlife. In short: You go from owning a large percentage of a financially distressed Swedish/Danish biotech company to owning a small percentage of a large, Chinese-controlled medtech company on the Swedish stock exchange that determines everything and can redeem the shares at a price set by them without notice. Can you see what's happening to your investment?
- ·13.5.Just saw the Q1 report and noticed that the company only has 3 employees??? They won't get much development done or sales from that. The Warthoe family seems to live mostly off the shareholders' continuous capital increases.·22.5. · MuokattuYes, they will probably be in an early growth phase until they retire as millionaires (In this phase it's perfectly fine to milk the shareholders through share issues, as much as one wants) Ref report comment I think the stock exchanges should impose more requirements on the companies and protect the small shareholders much more.
- ·12.5.Losses in all periods, despite capital injections?·13.5.It remains the same with this company. It is a company consisting solely of a few people who live on salaries costing millions paid by everyone else. Now they have worked on this project for over 20 years and they still haven't managed to make money from their idea. And the new board consists of old acquaintances who were also part of the original project, but who also seem to just want to enrich themselves. Whether it will ever amount to anything, I doubt. So I will also not throw more money after them in connection with more share issues. What I have now, must sink or swim.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 50 | - | - | ||
| 548 | - | - | ||
| 14 000 | - | - | ||
| 4 270 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 20.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 20.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenI almost don't know whether to laugh or cry about this stock.
- ·19.5. · MuokattuJust stumbled upon some facts: Thomas Warthoe (CEO) and Peter Warthoe (CSO) are brothers. The two are known as biotech entrepreneurs and have together founded several companies in the healthcare sector, including the Danish diagnostics company Qlife Holding, which is behind the home testing platform Egoo Health. Atonomics A/S is the brothers' most significant bankruptcy. The company existed for over 15 years and raised massive amounts of capital along the way, which was lost in the crash. Estimated loss/Investments: Over the years, the company raised between 100 and 200 million DKK from external investors, funds, and partners. Among the major investors were the listed biotech company NeuroSearch (which during the period injected over 40-50 million DKK into the company in the form of share purchases and convertible loans) as well as foreign private equity funds like Syndicate. Historical results leading up to the bankruptcy: The company almost exclusively reported losses throughout its lifetime, as it was purely a development company. In the last years before the bankruptcy (2015–2017), annual losses typically ranged from 10–25 million DKK per year, as cash ran out and the Trace product did not achieve its final commercial breakthrough. Who suffered the loss? Primarily the professional venture investors and companies (like NeuroSearch) who had the value of their shares and loans wiped out. Their own companies have also closed with losses. The finances of the listed parent company Qlife Holding AB are characterized by large losses, very low revenue, and an ongoing need for capital injections to keep the business and the development of the Egoo Health platform alive. Revenue: The company's revenue is extremely modest. For the entire financial year 2025, total revenue only amounted to 324,000 Swedish kronor (kSEK). In the first quarter of 2026, revenue further decreased to just 21,000 SEK. Operating result (EBITDA): The annual result for 2025 landed at a massive operating loss of -18.1 million SEK. Operations cost the company around 5.5 million SEK per quarter. Since the company has carried out massive public share issues to survive, the majority of the company's share capital is today owned by thousands of private and smaller investors. The planned reverse takeover has enormous consequences for the current shareholders in Qlife Holding. In reality, the maneuver means that the company completely changes its identity and financial foundation. Here is a concrete review of what the agreement means for you as a shareholder: 1. Strong mathematical dilution (Ownership share shrinks) When Qlife acquires the much larger Chinese Hipro Biotech, payment is not made with cash, but by issuing an enormous amount of brand new Qlife shares, which are given to the Chinese owners. Before the merger: The current shareholders today own 100 % of Qlife Holding. After the merger: The current shareholders will together only own 16.7 % of the new, combined company. The Chinese owners take over the remaining 83.3 %. Your personal ownership share in the company will, in other words, be drastically cut. 2. You suddenly own a part of a profitable billion-dollar business. Although your percentage ownership share becomes smaller, the value behind your share changes fundamentally: Now: You own a part of a company with minimal revenue, double-digit million losses, and an acute risk of bankruptcy. After the merger: You own a smaller piece of a much larger, well-established, and already profitable Chinese diagnostics group with massive production and distribution networks. The total value of the company is expected to increase significantly if the merger is approved. 3. No compulsory redemption (You keep your shares) When an investor buys more than 30 % of a listed company, it normally triggers a statutory obligation to make a takeover bid to all other shareholders (mandatory takeover offer). Hipro's founder, Hao Shushun, who will end up owning 37.7 % of the company, is, however, seeking an exemption from this rule. This means that you will not be forced to sell your shares. Your current Qlife shares will remain in your custody account, but the company will most likely change its name on the Stockholm stock exchange. 4. Extended waiting time and risk Since the stock exchange (Nasdaq) has rejected the original Chinese company structure ("Red Chip"), the companies have had to extend the deadline to close the deal until December 31, 2026. As a shareholder, you must be prepared for the share price to be characterized by great uncertainty and price fluctuations for the next long period, while advisors try to find a new legal model that the Swedish stock exchange authorities can approve. The deal is also conditional on it finally being voted through at an upcoming general meeting in Qlife. In short: You go from owning a large percentage of a financially distressed Swedish/Danish biotech company to owning a small percentage of a large, Chinese-controlled medtech company on the Swedish stock exchange that determines everything and can redeem the shares at a price set by them without notice. Can you see what's happening to your investment?
- ·13.5.Just saw the Q1 report and noticed that the company only has 3 employees??? They won't get much development done or sales from that. The Warthoe family seems to live mostly off the shareholders' continuous capital increases.·22.5. · MuokattuYes, they will probably be in an early growth phase until they retire as millionaires (In this phase it's perfectly fine to milk the shareholders through share issues, as much as one wants) Ref report comment I think the stock exchanges should impose more requirements on the companies and protect the small shareholders much more.
- ·12.5.Losses in all periods, despite capital injections?·13.5.It remains the same with this company. It is a company consisting solely of a few people who live on salaries costing millions paid by everyone else. Now they have worked on this project for over 20 years and they still haven't managed to make money from their idea. And the new board consists of old acquaintances who were also part of the original project, but who also seem to just want to enrich themselves. Whether it will ever amount to anything, I doubt. So I will also not throw more money after them in connection with more share issues. What I have now, must sink or swim.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 50 | - | - | ||
| 548 | - | - | ||
| 14 000 | - | - | ||
| 4 270 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 123 965 | 123 965 | 0 | 0 |